Ultrasound-Guided Percutaneous Radiofrequency for the Treatment of Morton’s Neuroma

Purpose Morton’s neuroma (MN) is a leading cause of disability. The purpose of this study was to investigate the effectiveness of radiofrequency (RF) in patients with chronic pain refractory to conservative therapies. Methods Between September 2012 and December 2016, RF was performed on 52 patients....

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular and interventional radiology 2018, Vol.41 (1), p.137-144
Main Authors: Masala, Salvatore, Cuzzolino, Alessandro, Morini, Marco, Raguso, Mario, Fiori, Roberto
Format: Article
Language:English
Subjects:
Cardiology
Chronic pain
Clinical Investigation
Complications
Imaging
Informed consent
Medicine
Medicine & Public Health
Nuclear Medicine
Pain
Patients
Quality of life
Radio frequency
Radiology
Tumors
Ultrasound
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Morton’s neuroma (MN) is a leading cause of disability. The purpose of this study was to investigate the effectiveness of radiofrequency (RF) in patients with chronic pain refractory to conservative therapies. Methods Between September 2012 and December 2016, RF was performed on 52 patients. A sterile RF needle probe (22G, 5-cm needle with 10-mm electrode active tip) was inserted between the toes into the intermetatarsal space at the center of the lesion. Potential complications of the intervention and post-procedure care were examined. All patients provided written, informed consent. All percutaneous procedures were performed with the NeuroTherm ® NT1100 ( Neurotherm Inc., M. ) device and using ultrasound guidance (Philips IU22). Continuous RF was performed with one cycle of 90 s and with the probe tip maintaining a temperature of 85 °C (impedance 95–210 mΩ). Results Mean VAS score before the procedures was 9.0 ± 0.6. A reduction of pain intensity was achieved after 1 week by RF (mean VAS scores 3.7 ± 0.9; p  
ISSN:0174-1551
1432-086X
DOI:10.1007/s00270-017-1786-y